Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Esophageal Cancer | Research

Survival outcomes of esophageal cancer patients with recurrence after curative treatments

Authors: Kotaro Sugawara, Daiji Oka, Hiroki Hara, Takako Yoshii, Hiroki Ushijima, Shigehiro Kudo, Takashi Fukuda

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Little is known about predictive factors for survival outcomes of esophageal carcinoma (EC) patients who developed recurrence after undergoing multimodal therapies. We aimed to investigate long-term outcomes and identify prognostic factors in patients with relapsed EC, focusing especially on those with oligometastasis (OM).

Methods

EC patients who developed recurrence after curative treatments (radical esophagectomy or definitive chemoradiotherapy (dCRT)) between 2010 and 2017 were reviewed. Multivariate Cox hazards models were applied to determine independent predictors of poor post-recurrence survival (PRS).

Results

In total, 178 patients were included. The median PRS was 12.9 months. Of the 178 patients, 98 had OM and 80 non-OM (NOM) disease. The survival outcomes of patients with OM were significantly better than those of patients with NOM (P < 0.01). Surgical treatments provided significantly better survival outcomes than CRT or chemo-/radiotherapy alone (3-year overall survival (OS); 78.1% vs. 42.5% vs. 28.9%, P < 0.01), mainly due to prolonging survival after the recurrence (3-year PRS 62.9% vs. 16.7% vs. 16.2%, P < 0.01). Multivariable analysis focusing on patients with OM revealed cStage III-IV disease (P < 0.01), high GPS at the time of recurrence (P = 0.02) and non-curative treatments (P < 0.01), to be independently associated with poor PRS. In contrast, in patients with NOM, no independent predictors for poor PRS were identified.

Conclusions

The survival outcomes of patients with relapsed EC remain poor. Surgical treatments could provide survival benefits for patients with recurrent EC, especially for patients with OM.
Appendix
Available only for authorised users
Literature
1.
Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus: Official Journal of the Japan Esophageal Society 2023:1–30.
2.
Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus: Official Journal of the Japan Esophageal Society 2023.
3.
Kalff MC, Henckens SPG, Voeten DM, Heineman DJ, Hulshof M, van Laarhoven HWM, Eshuis WJ, Baas PC, Bahadoer RR, Belt EJT, et al. Recurrent Disease after Esophageal Cancer Surgery: a Substudy of the Dutch Nationwide Ivory Study. Ann Surg. 2022;276(5):806–13.CrossRefPubMed
4.
Lou F, Sima CS, Adusumilli PS, Bains MS, Sarkaria IS, Rusch VW, Rizk NP. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol. 2013;8(12):1558–62.CrossRefPubMedPubMedCentral
5.
Yamashita K, Watanabe M, Mine S, Kurogochi T, Okamura A, Hayami M, Imamura Y. Patterns and outcomes of recurrent Esophageal Cancer after curative esophagectomy. World J Surg. 2017;41(9):2337–44.CrossRefPubMed
6.
Parry K, Visser E, van Rossum PS, Mohammad NH, Ruurda JP, van Hillegersberg R. Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent. Ann Surg Oncol. 2015;22(Suppl 3):1292–300.CrossRefPubMedCentral
7.
Ohkura Y, Shindoh J, Ueno M, Iizuka T, Udagawa H. Clinicopathologic characteristics of Oligometastases from Esophageal Cancer and Long-Term outcomes of Resection. Ann Surg Oncol. 2020;27(3):651–9.CrossRefPubMed
8.
Ghaly G, Harrison S, Kamel MK, Rahouma M, Nasar A, Port JL, Stiles BM, Altorki NK. Predictors of Survival after treatment of Oligometastases after Esophagectomy. Ann Thorac Surg. 2018;105(2):357–62.CrossRefPubMed
9.
Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Mori M, Doki Y. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18(12):3353–61.CrossRefPubMed
10.
Nobel TB, Sihag S, Xing X, Eljalby M, Hsu M, Tan KS, Sewell DB, Bains MS, Janjigian Y, Wu A, et al. Oligometastases after curative esophagectomy are not one size fits all. Ann Thorac Surg. 2021;112(6):1775–81.CrossRefPubMedPubMedCentral
11.
Morinaga T, Iwatsuki M, Yamashita K, Harada K, Kurashige J, Nagai Y, Iwagami S, Baba Y, Yoshida N, Baba H. Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma. Surg Today. 2021;51(5):798–806.CrossRefPubMed
12.
Depypere L, Lerut T, Moons J, Coosemans W, Decker G, Van Veer H, De Leyn P, Nafteux P. Isolated local recurrence or solitary solid organ Metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2017;30(1):1–8.PubMed
13.
Hiyoshi Y, Morita M, Kawano H, Otsu H, Ando K, Ito S, Miyamoto Y, Sakamoto Y, Saeki H, Oki E, et al. Clinical significance of surgical resection for the recurrence of Esophageal cancer after radical esophagectomy. Ann Surg Oncol. 2015;22(1):240–6.CrossRefPubMed
14.
Tsai PC, Chien HC, Hsu PK, Hung JJ, Huang CS, Hsu WH, Hsu HS. Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy. BMC Cancer. 2022;22(1):637.CrossRefPubMedPubMedCentral
15.
Brierley JGMKWC. TNM classification of malignant tumours, 8th Edition; 2017.
16.
Sugawara K, Yagi K, Okumura Y, Aikou S, Yamashita H, Seto Y. Survival prediction capabilities of preoperative inflammatory and nutritional status in esophageal squamous cell carcinoma patients. World J Surg. 2022;46(3):639–47.CrossRefPubMed
17.
Hoshino S, Takeuchi M, Kawakubo H, Matsuda S, Mayanagi S, Irino T, Fukuda K, Nakamura R, Wada N, Kitagawa Y. Usefulness of neutrophil to lymphocyte ratio at recurrence for Predicting Long-Term outcomes in patients with recurrent esophageal squamous cell carcinoma. Ann Surg Oncol. 2021;28(6):3001–8.CrossRefPubMed
18.
Sugawara K, Mori K, Yagi K, Aikou S, Uemura Y, Yamashita H, Seto Y. Association of preoperative inflammation-based prognostic score with survival in patients undergoing salvage esophagectomy. Dis Esophagus 2019, 32(4).
19.
Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus: Official Journal of the Japan Esophageal Society. 2019;16(1):1–24.CrossRefPubMed
20.
Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.CrossRefPubMed
21.
Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104(11):1455–60.CrossRefPubMedPubMedCentral
22.
Mayanagi S, Haneda R, Inoue M, Ishii K, Tsubosa Y. Selective lymphadenectomy for Salvage Esophagectomy in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2022;29(8):4863–70.CrossRefPubMed
23.
Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–12.CrossRefPubMedPubMedCentral
24.
Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermpas P, Baumert BG, Hurkmans C, Høyer M, Langendijk JA, Kaidar-Person O, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022;23(10):e469–78.CrossRefPubMed
25.
Sugawara K, Yagi K, Okumura Y, Nishida M, Aikou S, Yamashita H, Yamashita H, Seto Y. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage Surgery for T4 esophageal squamous cell carcinoma. Int J Clin Oncol. 2020;25(4):552–60.CrossRefPubMed
26.
Sugawara K, Fukuda T, Kishimoto Y, Oka D, Tanaka Y, Hara H, Yoshii T, Kawashima Y. Impacts of pretreatment esophageal stenosis on survival of esophageal cancer patients. Ann Surg Oncol 2022, In Press.
27.
Ichikawa H, Kosugi S, Nakagawa S, Kanda T, Tsuchida M, Koike T, Tanaka O, Hatakeyama K. Operative treatment for metachronous pulmonary Metastasis from esophageal carcinoma. Surgery. 2011;149(2):164–70.CrossRefPubMed
28.
Ichida H, Imamura H, Yoshimoto J, Sugo H, Kajiyama Y, Tsurumaru M, Suzuki K, Ishizaki Y, Kawasaki S. Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma. World J Surg. 2013;37(2):398–407.CrossRefPubMed
29.
Kobayashi N, Kohno T, Haruta S, Fujimori S, Shinohara H, Ueno M, Udagawa H. Pulmonary metastasectomy secondary to esophageal carcinoma: long-term survival and prognostic factors. Ann Surg Oncol. 2014;21(Suppl 3):365–9.CrossRef
30.
Liu J, Wei Z, Wang Y, Xia Z, Zhao G. Hepatic resection for post-operative solitary liver Metastasis from oesophageal squamous cell carcinoma. ANZ J Surg. 2018;88(4):E252–e256.CrossRefPubMed
31.
Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al. Neoadjuvant chemoradiotherapy plus Surgery versus Surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefPubMed
Metadata
Title
Survival outcomes of esophageal cancer patients with recurrence after curative treatments
Authors
Kotaro Sugawara
Daiji Oka
Hiroki Hara
Takako Yoshii
Hiroki Ushijima
Shigehiro Kudo
Takashi Fukuda
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11568-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis

Research article

PD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia

Research

Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study

Study Protocol

Promoting physical activity through supervised vs motivational behavior change interventions in breast cancer survivors on aromatase inhibitors (PAC-WOMAN): protocol for a 3-arm pragmatic randomized controlled trial

Study Protocol

NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases

Study Protocol

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits